Evaluation of safety for flibanserin

References

• Borsini F, Giraldo E, Monferini E, et al. BIMT 17, a 5-HT2A receptor antagonist and 5-HT1A receptor full agonist in rat cerebral cortex. Naunyn Schmiedebergs Arch Pharmacol. 1995;352:276–282.
   PubMed Web of Science ®Google Scholar
• Borsini F, Ceci A, Bietti G, et al. BIMT 17, a 5-HT1A receptor agonist/5-HT2A receptor antagonist, directly activates postsynaptic 5-HT inhibitory responses in the rat cerebral cortex. Naunyn Schmiedebergs Arch Pharmacol. 1995;352:283–290.
   PubMed Web of Science ®Google Scholar
• Clayton AH, Dennerstein L, Pyke R, et al. Flibanserin: a potential treatment for hypoactive sexual desire disorder in premenopausal women. Womens Health (Lond). 2010;6:639–653.
   PubMedGoogle Scholar
• McGahuey CA, Gelenberg AJ, Laukes CA, et al. The Arizona Sexual Experience Scale (ASEX): reliability and validity. J Sex Marital Ther. 2000;26:25–40.
   PubMed Web of Science ®Google Scholar
• Parish S, Hahn SR. Hypoactive sexual desire disorder: A review of epidemiology, biopsychology, diagnosis, and treatment. Sex Med Rev. 2016;4:103–120.
   PubMedGoogle Scholar
• Parish SJ, Goldstein AT, Goldstein SW, et al. Toward a more evidence-based nosology and nomenclature for female sexual dysfunctions—part II. J Sex Med. 2016;13:1888–1906.
   PubMed Web of Science ®Google Scholar
• Goldstein I, Kim NN, Clayton AH, et al. Hypoactive sexual desire disorder: International Society for the Study of Women’s Sexual Health (ISSWSH) expert consensus panel review. Mayo Clin Proc. 2017;92:114–128.
   PubMed Web of Science ®Google Scholar
• Clayton AH, Goldstein I, Kim NN, et al. The international society for the study of women’s sexual health process of care for management of hypoactive sexual desire disorder in women. Mayo Clin Proc. 2018;93:467–487.
   PubMed Web of Science ®Google Scholar
• Shifren JL, Monz BU, Russo PA, et al. Sexual problems and distress in United States women: prevalence and correlates. Obstet Gynecol. 2008;112:970–978.
   PubMed Web of Science ®Google Scholar
• West SL, D’Aloisio AA, Agans RP, et al. Prevalence of low sexual desire and hypoactive sexual desire disorder in a nationally representative sample of US women. Arch Intern Med. 2008;168:1441–1449.
   PubMed Web of Science ®Google Scholar
• Hayes RD, Dennerstein L, Bennett CM, et al. Relationship between hypoactive sexual desire disorder and aging. Fertil Steril. 2007;87:107–112.
   PubMed Web of Science ®Google Scholar
• Leiblum SR, Koochaki PE, Rodenberg CA, et al. Hypoactive sexual desire disorder in postmenopausal women: US results from the Women’s International Study of Health and Sexuality (WISHeS). Menopause. 2006;13:46–56.
   PubMed Web of Science ®Google Scholar
• Foley K, Foley D, Johnson BH. Healthcare resource utilization and expenditures of women diagnosed with hypoactive sexual desire disorder. J Med Econ. 2010;13:583–590.
   PubMedGoogle Scholar
• Biddle AK, West SL, D’Aloisio AA, et al. Hypoactive sexual desire disorder in postmenopausal women: quality of life and health burden. Value Health. 2009;12:763–772.
   PubMed Web of Science ®Google Scholar
• Kingsberg SA. Attitudinal survey of women living with low sexual desire. J Womens Health (Larchmt). 2014;23:817–823.
   PubMed Web of Science ®Google Scholar
• Dennerstein L, Koochaki P, Barton I, et al. Hypoactive sexual desire disorder in menopausal women: a survey of Western European women. J Sex Med. 2006;3:212–222.
   PubMed Web of Science ®Google Scholar
• Clayton AH, Maserejian NN, Connor MK, et al. Depression in premenopausal women with HSDD: baseline findings from the HSDD Registry for women. Psychosom Med. 2012;74:305–311.
   PubMed Web of Science ®Google Scholar
• Addyi® (flibanserin) tablets, for oral use [prescribing information in US]. Raleigh, NC: Sprout Pharmaceuticals, Inc.; 2019.
   Google Scholar
• Addyi® (flibanserin) tablets, for oral use [product monograph in CANADA]. Raleigh, NC: Sprout Pharmaceuticals, Inc.; 2018.
   Google Scholar
• Food and Drug Administration. Addyi tablets - FDA staff reviews, labels and action letters. 2015. cited 2019 Dec 3. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/022526Orig1s000TOC.cfm.
   Google Scholar
• Summary basis of decision – addyi. Health Canada. April 2019. cited 2019 Dec 3. https://hpr-rps.hres.ca/reg-content/summary-basis-decision-detailTwo.php?linkID=SBD00392.
   Google Scholar
• Woloshin S, Schwartz LM. US food and drug administration approval of flibanserin: even the Score does not add up. JAMA Intern Med. 2016;176:439–442.
   PubMed Web of Science ®Google Scholar
• Anderson R, Moffatt CE. Ignorance is not bliss: if we don’t understand hypoactive sexual desire disorder, how can flibanserin treat it? Commentary. J Sex Med. 2018;15:273–283.
   PubMed Web of Science ®Google Scholar
• Stahl SM. Mechanism of action of flibanserin, a multifunctional serotonin agonist and antagonist (MSAA), in hypoactive sexual desire disorder. CNS Spectr. 2015;20:1–6.
   PubMed Web of Science ®Google Scholar
• Arnow BA, Millheiser L, Garrett A, et al. Women with hypoactive sexual desire disorder compared to normal females: a functional magnetic resonance imaging study. Neuroscience. 2009;158:484–502.
   PubMed Web of Science ®Google Scholar
• Bianchi-Demicheli F, Cojan Y, Waber L, et al. Neural bases of hypoactive sexual desire disorder in women: an event-related FMRI study. J Sex Med. 2011;8:2546–2559.
   PubMed Web of Science ®Google Scholar
• Woodard TL, Nowak NT, Balon R, et al. Brain activation patterns in women with acquired hypoactive sexual desire disorder and women with normal sexual function: a cross-sectional pilot study. Fertil Steril. 2013;100:1068–1076.
   PubMed Web of Science ®Google Scholar
• Pfaus JG. Pathways of sexual desire. J Sex Med. 2009;6:1506–1533.
   PubMed Web of Science ®Google Scholar
• Allers KA, Dremencov E, Ceci A, et al. Acute and repeated flibanserin administration in female rats modulates monoamines differentially across brain areas: a microdialysis study. J Sex Med. 2010;7:1757–1767.
   PubMed Web of Science ®Google Scholar
• Borsini F, Evans K, Jason K, et al. Pharmacology of flibanserin. CNS Drug Rev. 2002;8:117–142.
   PubMedGoogle Scholar
• Invernizzi RW, Sacchetti G, Parini S, et al. Flibanserin, a potential antidepressant drug, lowers 5-HT and raises dopamine and noradrenaline in the rat prefrontal cortex dialysate: role of 5-HT(1A) receptors. Br J Pharmacol. 2003;139:1281–1288.
   PubMed Web of Science ®Google Scholar
• Marazziti D, Palego L, Giromella A, et al. Region-dependent effects of flibanserin and buspirone on adenylyl cyclase activity in the human brain. Int J Neuropsychopharmacol. 2002;5:131–140.
   PubMed Web of Science ®Google Scholar
• Stahl SM, Sommer B, Allers KA. Multifunctional pharmacology of flibanserin: possible mechanism of therapeutic action in hypoactive sexual desire disorder. J Sex Med. 2011;8:15–27.
   PubMed Web of Science ®Google Scholar
• Brambilla A, Baschirotto A, Grippa N, et al. Effect of flibanserin (BIMT 17), fluoxetine, 8-OH-DPAT and buspirone on serotonin synthesis in rat brain. Eur Neuropsychopharmacol. 1999;10:63–67.
   PubMed Web of Science ®Google Scholar
• Simon JA, Thorp J, Millheiser L. Flibanserin for premenopausal hypoactive sexual desire disorder: pooled analysis of clinical trials. J Womens Health (Larchmt). 2019;28:769–777.
   PubMed Web of Science ®Google Scholar
• Derogatis LR, Komer L, Katz M, et al. Treatment of hypoactive sexual desire disorder in premenopausal women: efficacy of flibanserin in the VIOLET study. J Sex Med. 2012;9:1074–1085.
   PubMed Web of Science ®Google Scholar
• Katz M, Derogatis LR, Ackerman R, et al. Efficacy of flibanserin in women with hypoactive sexual desire disorder: results from the BEGONIA trial. J Sex Med. 2013;10:1807–1815.
   PubMed Web of Science ®Google Scholar
• Thorp J, Simon J, Dattani D, et al. Treatment of hypoactive sexual desire disorder in premenopausal women: efficacy of flibanserin in the DAISY study. J Sex Med. 2012;9:793–804.
   PubMed Web of Science ®Google Scholar
• Sprout Pharmaceuticals. Data on file.
   Google Scholar
• Simon JA, Kingsberg SA, Shumel B, et al. Efficacy and safety of flibanserin in postmenopausal women with hypoactive sexual desire disorder: results of the SNOWDROP trial. Menopause. 2014;21:633–640.
   PubMed Web of Science ®Google Scholar
• Rosen RC, Maserejian NN, Connor MK, et al. Characteristics of premenopausal and postmenopausal women with acquired, generalized hypoactive sexual desire disorder: the hypoactive sexual desire disorder registry for women. Menopause. 2012;19:396–405.
   PubMed Web of Science ®Google Scholar
• Connor MK, Maserejian NN, De Rogatis L, et al. Sexual desire, distress, and associated factors in premenopausal women: preliminary findings from the hypoactive sexual desire disorder registry for women. J Sex Marital Ther. 2011;37:176–189.
   PubMed Web of Science ®Google Scholar
• Johnson-Agbakwu C, Brown L, Yuan J, et al. Effects of flibanserin on the pharmacokinetics of a combined ethinylestradiol/levonorgestrel oral contraceptive in healthy premenopausal women: A randomized crossover study. Clin Ther. 2018;40(1):64–73.
   PubMed Web of Science ®Google Scholar
• Kay GG, Hochadel T, Sicard E, et al. Next-day residual effects of flibanserin on simulated driving performance in premenopausal women. Hum Psychopharmacol. 2017;32:e2603.
   PubMed Web of Science ®Google Scholar
• Stevens DM, Weems JM, Brown L, et al. The pharmacodynamic effects of combined administration of flibanserin and alcohol. J Clin Pharm Ther. 2017;42:598–606.
   PubMed Web of Science ®Google Scholar
• Simon JA, Clayton AH, Parish SJ, et al. Effects of alcohol administered with flibanserin in healthy premenopausal women: A randomized, double-blind, single-dose crossover study. J Sex Med. 2019; In Press. doi: 10.1016/j.jsxm.2019.10.004
   Web of Science ®Google Scholar
• Simon JA, Clayton AH, Kingsberg SA, et al. Effects of timing of flibanserin administration relative to alcohol intake in healthy premenopausal women: A randomized, double-blind, crossover study. J Sex Med. 2019;16:1779–1786.
   Web of Science ®Google Scholar
• Millheiser L, Clayton AH, Parish SJ, et al. Safety and tolerability of evening ethanol consumption and bedtime administration of flibanserin in healthy premenopausal female subjects. Sex Med. 2019;7:418–424.
   PubMed Web of Science ®Google Scholar
• Clayton AH, Croft HA, Yuan J, et al. Safety of flibanserin in women treated with antidepressants: A randomized, placebo-controlled study. J Sex Med. 2018;15:43–51.
   PubMed Web of Science ®Google Scholar
• Granzella N, Chen BC, Baird GS, et al. Flibanserin toxicity in a toddler following ingestion. Clin Toxicol. 2018;56:226–228.
   PubMed Web of Science ®Google Scholar
• Vyleesi® [prescribing information]. Waltham, MA, AMAG Pharmaceuticals. Revised June 2019. Accessed 2019 Aug 20
   Google Scholar
• Somboonporn W, Davis S, Seif MW, et al. Testosterone for peri- and postmenopausal women. Cochrane Database Syst Rev. 2005;(4):CD004509.
   Google Scholar
• Abdallah RT, Simon JA. Testosterone therapy in women: its role in the management of hypoactive sexual desire disorder. Int J Impot Res. 2007;19:458–463.
   PubMed Web of Science ®Google Scholar
• Hubayter Z, Simon JA. Testosterone therapy for sexual dysfunction in postmenopausal women. Climacteric. 2008;11:181–191.
   PubMed Web of Science ®Google Scholar
• Krapf JM, Simon JA. The role of testosterone in the management of hypoactive sexual desire disorder in postmenopausal women. Maturitas. 2009;63:213–219.
   PubMed Web of Science ®Google Scholar
• Davis SR, Braunstein GD. Efficacy and safety of testosterone in the management of hypoactive sexual desire disorder in postmenopausal women. J Sex Med. 2012;9:1134–1148.
   PubMed Web of Science ®Google Scholar
• Davis SR, Wahlin-Jacobsen S. Testosterone in women–the clinical significance. Lancet Diabetes Endocrinol. 2015;3:980–992.
   PubMed Web of Science ®Google Scholar
• Simon J, Braunstein G, Nachtigall L, et al. Testosterone patch increases sexual activity and desire in surgically menopausal women with hypoactive sexual desire disorder. J Clin Endocrinol Metab. 2005;90:5226–5233.
   PubMed Web of Science ®Google Scholar
• Dimitrakakis C, Jones R, Liu A, et al. Breast cancer incidence in postmenopausal women using testosterone in addition to usual hormone therapy. Menopause. 2004;11:531–534.
   PubMed Web of Science ®Google Scholar
• Davis SR, Wolfe R, Farrugia H, et al. The incidence of invasive breast cancer among women prescribed testosterone for low libido. J Sex Med. 2009;6:1850–1856.
   PubMed Web of Science ®Google Scholar
• Glaser RL, Dimitrakakis C. Reduced breast cancer incidence in women treated with subcutaneous testosterone, or testosterone with anastrozole: a prospective, observational study. Maturitas. 2013;76:342–349.
   PubMed Web of Science ®Google Scholar
• Segraves RT, Croft H, Kavoussi R, et al. Bupropion sustained release (SR) for the treatment of hypoactive sexual desire disorder (HSDD) in non-depressed women. J Sex Marital Ther. 2001;27:303–316.
   PubMed Web of Science ®Google Scholar
• Wellbutrin® [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline. Revised April 2016. Accessed 2019 Aug 20.
   Google Scholar
• BuSpar® [prescribing information]. Princeton, NJ: Bristol-Myers Squibb. Revised May 2017. Accessed 2019 Aug 20.
   Google Scholar